

10 April 2018

To: Recipients of M100, 28th ed.  
 From: Jennifer K. Adams, MT(ASCP), MSHA  
 Vice President, Standards and Quality  
 Subject: Correction

This notification is to inform you of a correction made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 28th ed. The correction is described below and shown as highlighted and stricken text in the table excerpt.

**Table 4A-2, Disk Diffusion QC Ranges for Nonfastidious Organisms and B-Lactam Combination Agents:**

The disk content provided in Table 4A-2 for ceftazidime-avibactam is listed incorrectly as “30/15 µg.”

In Table 4A-2, the disk content for ceftazidime-avibactam has been corrected to read “30/20 µg.”

The Table 4A-2 correction is shown in the table excerpt below.

**Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and B-Lactam Combination Agents**

Antimicrobial Agent	Disk Content	QC Organisms and Characteristics					
		<i>Escherichia coli</i> ATCC <sup>®a</sup> 25922	<i>Pseudomonas aeruginosa</i> ATCC <sup>®</sup> 27853	<i>Staphylococcus aureus</i> ATCC <sup>®</sup> 25923	<i>Escherichia coli</i> ATCC <sup>®b,c</sup> 35218	<i>Klebsiella pneumoniae</i> ATCC <sup>®</sup> 700603 <sup>b,c</sup>	
		B-lactamase negative	Inducible AmpC	B-lactamase negative, <i>mecA</i> negative	TEM-1	SHV-18 OXA-2 Mutations in OmpK35 and OmpK37 TEM-1	
MIC QC ranges, mm							
Ceftazidime-avibactam	30/ <del>15</del> 20 µg	27-35	25-31	16-22	28-35	21-27 <sup>e</sup>	

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.